Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Inflammation 1Disease Progression 1Arthritis, Rheumatoid 1

Interventions

umbralisib 1ublituximab 1marizomib 1fludarabine phosphate 1fludarabine 1enzastaurin 1durvalumab 1carotuximab 1brigatinib 1binimetinib 1axicabtagene ciloleucel 1Zoledronic Acid 1Vitamin D 1Receptors, Interleukin-6 1Oxaliplatin 1Leucovorin 1Irinotecan 1Interleukin 1 Receptor Antagonist Protein 1Gemcitabine 1Folfox protocol 1Fluorouracil 1Cyclophosphamide 1Cisplatin 1Calcium 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Disease Progression × Interleukin 1 Receptor Antagonist Protein × Clear all
NCT04205838 2026-02-27

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
23 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡